Bird Flu Vaccine 2023

Authored by
Staff
Last reviewed
February 5, 2023
Content Overview
Avian influenza (bird flu) virus vaccines have been U.S. FDA approved.

Bird Flu (Avian Influenza) Vaccines 2023

The U.S. government has approved a vaccine for one type of avian influenza (bird flu) virus and could distribute it if a person-to-person outbreak occurs. The U.S. Food and Drug Administration (FDA) authorized CSL Seqirus' Audenz™ monovalent cell-based vaccine on January 31, 2020. A Supplemental Approval in 2021 for use in persons at increased risk of exposure to the influenza A virus H5N1 subtype.

Moreover, the FDA says annual flu shots are unlikely to protect people during avian influenza (bird flu) pandemics.

Bird Flu Vaccine Candidates

CSL Seqirus announced in 2022 that the U.S. Biomedical Advanced Research and Development Authority (BARDA) selected the Massachusetts-based company to deliver an H5N8 A/Astrakhan3212/2020 (H5N8) virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in 2023. Under the $30.1 million agreement, BARDA is partnering with GSK and CSL Seqirus to manufacture investigational lots of H5N8 vaccines and clinically assess the safety, immunogenicity, and dose-sparing ability of adjuvants in combination with the manufactured vaccine candidates.

On October 5, 2022, CSL announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates. The data, published in Molecular Therapy – Methods and Clinical Development, indicate that the sa-mRNA influenza vaccine candidates produced a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1) (Swine flu).

The U.S. government awarded California-based Vir Bio a multi-year contract on October 4, 2022, with the potential for up to $1 billion to advance the development of a complete portfolio of innovative solutions (vaccines) to address influenza and other infectious disease threats.

The European Commission (EC) signed a framework contract on July 28, 2022, for the joint procurement of GSK's Adjupanrix, a pandemic influenza vaccine. EC Member States can purchase up to 85 million vaccine doses, if necessary, during an influenza pandemic.

Pandemic Influenza A Monoclonal Antibody

Vir Biotechnology, Inc. VIR-2482 is an intramuscularly administered investigational prophylactic monoclonal antibody that has demonstrated in vitro the ability to neutralize significant strains of influenza A that have arisen since the 1918 Spanish flu pandemic.

Bird Flu Medications

The U.S. CDC currently recommends antiviral medicines for people who contract bird flu. However, some evidence of antiviral resistance has been reported in HPAI Asian lineage avian influenza A(H5N1) viruses (“Asian H5N1 viruses”) and Asian lineage avian influenza A(H7N9) viruses.

Bird Flu Tests

The ECDC published on October 3, 2022: Testing and detection of zoonotic influenza virus infections in humans in the EU/EEA, and occupational safety and health measures for those exposed at work.

Bird Flu Outbreak News 2023

Avian flu outbreak news can be found on this web page.